To include your compound in the COVID-19 Resource Center, submit it here.

The Remune spat

While it surely is not unusual for researchers to disagree over the interpretation of data, those disputes generally don't become public. But such a dispute did break into the open last week between The Immune Response Corp. and the University of California at San Francisco, raising questions about how data should be published when the parties involved disagree. Perhaps even more important, the dispute raises the issue of corporate influence over the analysis of clinical data, as the company's interpretation is more positive than the UCSF

Read the full 863 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE